The company focuses on small molecule product candidates that target Toll-like receptor 8 (TLR8), including VTX-2337, a TLR8 agonist for the treatment of solid tumors and various cancers, and TLR8 antagonists for autoimmune diseases. VentiRx Pharmaceuticals also collaborates with Celgene Corporation and operates in Seattle and San Diego.